NCT07885995Not yet recruiting
EFFECT OF COMBINED VIRTUAL REALITY-GUIDED BREATHING AND AEROBIC TRAINING ON VENTILATORY FUNCTION IN PATIENTS WITH COPD
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This Single-blind, randomized controlled trial will evaluate the effects of 12 weeks of combined VR-guided diaphragmatic breathing (Flowborne) and VR-aerobic cycling (Kinneta) compared with conventional pulmonary rehabilitation in male and female patients aged 45-55 years with stable COPD (GOLD Stage II). Both groups will train three times weekly at 65-75% HRmax. Primary outcomes are diaphragmatic excursion and FEV₁, while secondary outcomes include FVC, FEV1/FVC ratio, 6MWT, Borg dyspnea score, smoking index, SpO₂, and CAT score. All outcomes will be assessed at the end of the 12-week intervention.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 11 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Cairo University
- Diseases
- COPD
- NCT number
- NCT07885995
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Nov 2026 to the primary completion date, Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute exacerbation of Chronic Obstructive Pulmonary Disease or recent hospitalization.
- Unstable cardiovascular disorders, such as:
- uncontrolled hypertension
- unstable angina
- recent myocardial infarction
- severe arrhythmias
- Severe musculoskeletal disorders limiting exercise performance.
- Neurological disorders affecting balance, gait, or exercise ability.
- Severe cognitive impairment or psychiatric disorders interfering with cooperation.
Who the study is looking for
- Sixty male patients with chronic obstructive pulmonary disease, diagnosed with stable COPD according to GOLD criteria, defined by spirometric evidence of GOLD stage II airflow limitation (FEV₁ ≥50% and \<80% predicted for stage II.
- Their age will range from 45-55s.
- Ability to use a VR headset after training
- Clinically stable condition with no acute exacerbation during the previous 4-6 weeks.
- Ability to ambulate independently and perform aerobic exercise safely.
- Medically cleared by a physician to participate in exercise training.
- Ability to understand and follow instructions.
- Stable pharmacological treatment for at least 4 weeks before participation.
- Patients willing to participate and sign informed consent.
Age in the registry: 45 years to 55 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.